NovAccess Global Inc. (XSNX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 2.80: the stock has moved about 180% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNovAccess Global Inc. (XSNX) trades at $0.0001. NovAccess Global Inc. is a biopharmaceutical company focused on developing immunotherapies for brain tumor patients. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for XSNX: XSNX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
NovAccess Global Inc. (XSNX) Healthcare & Pipeline Overview
NovAccess Global Inc. is a biopharmaceutical company specializing in the development of novel immunotherapies for the treatment of brain tumors. Operating within the competitive biotechnology sector, the company focuses on leveraging a patient's immune system to combat cancer, with research and development based in Chesterland, Ohio.
What Is the Investment Thesis for XSNX?
NovAccess Global Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on novel immunotherapies for brain tumors positions it in a niche market with significant unmet needs. However, with a market capitalization of $0.00 billion and negative P/E ratio, the company's financial stability and path to profitability are uncertain. Key value drivers include successful clinical trials and regulatory approvals for its immunotherapeutic candidates. The primary risk factors include the inherent challenges of drug development, potential setbacks in clinical trials, and the company's ability to secure funding for ongoing research and operations. The beta of 2.80 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
XSNX Key Highlights
Market capitalization of $0.00 billion, indicating a micro-cap company with limited resources.
- Negative P/E ratio, reflecting the company's current lack of profitability.
- Beta of 2.80, suggesting high volatility compared to the overall market.
- Focus on novel immunotherapies for brain tumors, a specialized area within the biotechnology sector.
- Small team of 3 employees, indicating a lean operational structure.
Who Are XSNX's Competitors?
XSNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.06 | +1.32% | $258M | 90 5-pillar |
| FENC Fennec Pharmaceuticals Inc. | $13.33 | -1.84% | $471M | 91 5-pillar |
| INDP Indaptus Therapeutics, Inc. | $3.13 | -4.86% | $481M | 60 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.07 | -2.26% | $540M | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XSNX's Key Strengths?
Focus on a specific niche market (brain tumor immunotherapy).
- Proprietary immunotherapeutic technologies.
- Potential for significant impact on patient outcomes.
- Small and agile team.
What Are XSNX's Weaknesses?
Limited financial resources.
- Small team size.
- Dependence on external funding.
- Early stage of development.
What Are the Key Risks for XSNX?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding for research and development.
- Setbacks or failures in clinical trials.
- Competition from larger, more established companies.
- Regulatory hurdles and delays in obtaining approvals.
- Limited financial resources and operational scale.
What Are XSNX's Competitive Advantages?
- Proprietary immunotherapeutic technologies.
- Specialized expertise in brain tumor immunotherapy.
- Potential for patent protection on novel therapies.
- First-mover advantage in a niche market.
What Does XSNX Do?
NovAccess Global Inc., incorporated in 1997 and headquartered in Chesterland, Ohio, is a biopharmaceutical company dedicated to pioneering novel immunotherapies for the treatment of brain tumors. The company's core focus lies in harnessing the power of a patient's own immune system to target and destroy cancer cells, representing a cutting-edge approach in the field of oncology. NovAccess Global is involved in the research and development of these specialized treatments, aiming to provide innovative solutions for patients battling brain tumors. The company operates primarily in the United States, concentrating its efforts on developing and potentially commercializing its immunotherapeutic technologies. With a small team of three employees, NovAccess Global is currently led by Dwain K. Morris-Irvin. The company's strategic direction revolves around advancing its research initiatives and navigating the complex regulatory landscape to bring its therapies to market.
What Products and Services Does XSNX Offer?
- Develop novel immunotherapies for brain tumor patients.
- Conduct research on utilizing the patient's immune system to attack cancer.
- Focus on cutting-edge research in the field of oncology.
- Aim to provide innovative treatment solutions for brain tumors.
- Engage in clinical trials to evaluate the safety and efficacy of their therapies.
- Seek regulatory approvals for their immunotherapeutic products.
How Does XSNX Make Money?
- Research and development of novel immunotherapies.
- Seeking partnerships and collaborations for funding and expertise.
- Potential revenue generation through licensing agreements.
- Future revenue from product sales upon regulatory approval.
What Industry Does XSNX Operate In?
NovAccess Global Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The market for cancer immunotherapies is expanding rapidly, driven by advancements in understanding the human immune system and its ability to fight cancer. The company faces competition from larger, more established biotechnology and pharmaceutical companies, as well as smaller, specialized firms focused on immunotherapy. Success in this industry requires significant capital investment, scientific expertise, and the ability to navigate complex regulatory pathways.
Who Are XSNX's Key Customers?
- Brain tumor patients.
- Healthcare providers.
- Hospitals and cancer treatment centers.
- Potential pharmaceutical partners.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
NovAccess Global Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for NovAccess Global Inc. stands at 76.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
NovAccess Global Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Dwain K. Morris-Irvin. XSNX has traded publicly since 1998.
XSNX Latest News
No recent news available for XSNX.
XSNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for XSNX.
Price Targets
Wall Street price target analysis for XSNX.
XSNX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for XSNX; grades run from A+ (80-100) to F (below 30).
Leadership: Dwain K. Morris-Irvin
CEO
Dwain K. Morris-Irvin serves as the CEO of NovAccess Global Inc. His background includes experience in managing small teams and guiding early-stage companies. His leadership is focused on steering NovAccess Global through the complex landscape of biopharmaceutical research and development. His expertise is crucial for navigating the challenges of bringing novel immunotherapies to market, particularly in the competitive field of oncology.
Track Record: Under Dwain K. Morris-Irvin's leadership, NovAccess Global Inc. has focused on advancing its research in immunotherapies for brain tumors. Key milestones include securing funding for research initiatives and progressing through preclinical development stages. His strategic decisions are centered on maximizing the potential of the company's proprietary technologies and building a strong foundation for future growth.
XSNX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NovAccess Global Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors and may be subject to greater risks. Investing in companies on the OTC Other tier requires a higher degree of due diligence and caution compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial information and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and market opportunity.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company has been incorporated since 1997, indicating some operational history.
- Focus on a specific area of biotechnology (brain tumor immunotherapy).
- Company has a CEO and a small team, suggesting some level of operational structure.
- Headquartered in Chesterland, Ohio.
NovAccess Global Inc. Healthcare Stock: Key Questions Answered
What are the main risks for XSNX?
The main risks for NovAccess Global Inc. include the inherent challenges of drug development, such as clinical trial failures and regulatory hurdles.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of financial disclosure.